

# Evaluation of global coagulation assays for assessment of clotting function and risk of venous thromboembolism in pregnancy

David O'Keefe<sup>1</sup>, A/Prof Lisa Hui<sup>1,2</sup>, Dr Prahlad Ho<sup>3</sup>, Dr Hui Yin Lim<sup>1,3</sup>

<sup>1</sup>The University of Melbourne, <sup>2</sup>Department of Obstetrics & Gynaecology, Northern Health, <sup>3</sup>Department of Haematology, Northern Health



THE UNIVERSITY OF  
MELBOURNE

Northern Health

## BACKGROUND

- Women are at higher risk of venous thromboembolism (VTE) in pregnancy and postpartum, which is a significant cause of morbidity and mortality<sup>1</sup>.
- Current routine coagulation tests cannot discern the physiological hypercoagulability of pregnancy.
- Current methods of assessing risk of VTE are limited to risk factor-based stratification drawn from case-control studies and consensus opinion.
- Global coagulation assays (GCA) include:
  - Thromboelastography (TEG)
  - Calibrated automated thrombography (CAT) – measuring thrombin generation
  - Overall haemostatic potential assay (OHP) – measuring fibrin generation
- GCA results may be more representative of the coagulation process and may be used clinically as an adjunct to predict the risk of VTE.

## AIMS & OBJECTIVES

To evaluate the ability of global coagulation assays to:

- Detect the hypercoagulability of pregnancy
- Differentiate coagulability amongst pregnant women of varying VTE risk profile, in particular women of varying BMI.

## METHODS

- This was a pilot prospective observational study conducted at Northern Health.
- Pregnant women at term undergoing elective Caesarean section at the Northern Hospital provided a single pre-operative blood sample.
- TEG was performed using citrated whole blood. CAT and OHP were performed using platelet-poor plasma, obtained by double centrifugation.
- Data from 47 healthy non-pregnant women aged 18-45 years from a concurrent study database were used as the control group<sup>2</sup>.

## CONCLUSIONS

- Pregnant women were significantly more hypercoagulable on most GCA parameters, compared with non-pregnant women.
- GCA results were significantly correlated with overweight and obesity in the pregnant population across all BMI groups.
- Larger studies are required to further investigate potential associations between GCA parameters and clinical risk factors for VTE in pregnancy and postpartum.

## REFERENCES

- Sultan AA, West J, Tata LJ, Fleming KM, Nelson-Piercy C, Grainge MJ. Risk of first venous thromboembolism in and around pregnancy: a population-based cohort study. *Br J Haematol*. 2012;156:366-73.
- Ho P, Ng C, Rigano J, Tacey M, Smith C, Donnan G, et al. Significant age, race and gender differences in global coagulation assays parameters in the normal population. *Thromb Res*. 2017;154:80-3.
- Nelson-Piercy C, MacCallum P, Mackillop L. Reducing the risk of thrombosis and embolism during pregnancy and the puerperium. Green-top guideline no. 73a. London: Royal College of Obstetricians & Gynaecologists; 2015.

Thank you to the maternity unit midwives and Dr Jonathan Tham for their assistance with data collection and Mark Tacey for assistance with statistical analysis.


This project was funded by a 2017 Northern Health Small Research Grant, courtesy of the Northern Health Foundation.

CONTACT: davidokeefe95@gmail.com


## RESULTS

Sixty women with term singleton pregnancies were included. 41.7% (n=25) were obese ( $\geq 30\text{kg/m}^2$ ) at booking and 88.3% (n=53) were multiparous.


### COMPARISON OF GCA RESULTS IN PREGNANT VS NON-PREGNANT WOMEN



**Figure 1. TEG showed hypercoagulability** in pregnant women with increased alpha-angle (rate of clot formation,  $p < 0.001$ ), increased maximum amplitude (maximum clot strength,  $p < 0.001$ ), decreased LY30 (a measure of fibrinolysis,  $p < 0.001$ ) and decreased R value (time until clot formation,  $p = 0.013$ ).




**Figure 2. CAT showed hypercoagulability** in pregnant women with increased endogenous thrombin potential (amount of thrombin generated,  $p < 0.001$ ), increased thrombin peak (maximum concentration of thrombin,  $p < 0.001$ ) and increased velocity index (rate of thrombin generation,  $p = 0.001$ ).



**Figure 3. OHP assay showed hypercoagulability** in pregnant women with increased overall coagulation potential (amount of fibrin generated,  $p < 0.001$ ) and increased overall haemostatic potential ( $p < 0.001$ ), indicating there was greater fibrin generation than fibrinolysis.

### COMPARISON OF GCA RESULTS WITHIN PREGNANT COHORT

- Women who qualified for antenatal or postpartum thromboprophylaxis based on a clinical VTE risk assessment did not have significantly different GCA results to those who did not qualify<sup>3</sup>.
- Women who were obese at booking ( $\geq 30\text{kg/m}^2$ , n=24) had a **higher clot strength** (maximum amplitude) compared to those of normal BMI (18.5-24.9 $\text{kg/m}^2$ , n=13) ( $p < 0.001$ ).
- When comparing all BMI groups, there was a significant increase in clot strength from normal BMI to all other groups ( $p < 0.001$ ) (Fig 4).



**Figure 4. Changes in maximum amplitude (using TEG) with BMI category.**  
\* : MA significantly different from normal BMI category 18.5-24.9 $\text{kg/m}^2$  ( $p < 0.001$ )  
◊ : Outlier (1.5 x the IQR)  
Box plots represent the range of data from 25th to 75th percentile; the middle bar represents the median value.